We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 18, 2020

CD19-Specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch Receptor Are Effective in Patients With PD-L1–Positive B-Cell Lymphoma

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
CD19-Specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients With PD-L1–Positive B-Cell Lymphoma
Clin. Cancer Res 2020 Oct 07;[EPub Ahead of Print], H Liu, W Lei, C Zhang, C Yang, J Wei, Q Guo, X Guo, Z Chen, Y Lu, KH Young, Z Lu, W Qian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading